Thromboprophylaxis for Newly Diagnosed Multiplemyeloma Patients Treated With Lenalidomide-Basedregimens: A Randomized Phase Iii Study of Aspirinvs Enoxaparin
Alessandra Larocca(Cornell University), Antonio Palumbo(Ospedale Vito Fazzi), Roberto Ria(University of Bari Aldo Moro), Tommasina Guglielmelli(Azienda Ospedaliero Universitaria San Giovanni Battista), Mario Boccadoro(University of Turin), Nicola Cascavilla, Giulia Benevolo(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Norbert Pescosta(Fondazione Gimema Onlus), Francesco Di Raimondo(University of Catania), Clotilde Cangialosi(Azienda Ospedaliero Universitaria San Giovanni Battista), Francesca Rossi(University of Siena), Tommaso Caravita di Toritto(Fondazione Gimema Onlus), Lucio Catalano(University of Naples Federico II), Magda Marcatti(Vita-Salute San Raffaele University), Mónica Galli(Ospedale Papa Giovanni XXIII), Federica Cavallo, D Rossi, Anna Baraldi(Fondazione Gimema Onlus), Luciano Masini(Casa di Cura Villa Garda), A. Nagler, Adriane Feijó Evangelista
Unknown
January 1, 2011
Cited by 0
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
|Leukemia|2008|808
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2023|538